| 在法国排名第2位的全球制药集团公司 |
| 在法国排名第2位,在欧洲排名第6位,在全球制药集团公司中排名第18位,在全球一百多个国家开展业务。赛诺菲～圣德拉堡集团公司在世界药品市场上占有一个重要的地位。 |
| 2nd
Pharmaceutical Group in France |
| Present
in more than 100 countries,2nd in France,6th in Europe,18th
pharmaceutical group worldwide,Sanofi-Synthélabo is a major
player on the pharmaceutical market. |
|
| 赛诺菲圣德拉堡在其主要涉及的4个治疗领域：心血管/血栓类、中枢神经系统、癌症和内科用药都有领先产品。 |
| 4
Therapeutic Areas |
 |
| Sanofi-Synthélabo
has leading products its four principal areas of expertise:cardiovascular/thrombosis,central
nervous system,oncology and internal medicine. |
| 52种药品正处于开发之中 |
| 赛诺菲圣德拉堡的科研开发中心富于创新且成绩卓越著，有15个研究开发中心，目前就52种药品正处于开发之中。 |
| 52
Compounds Under Development |
| Thanks
to an innovative and successful R&D,Sanofi-Synthélabo has
a portfolio of 52 compounds in development programs,15 Research&Development
centers in the world. |
| 集团的经济结构良好
Consolidated Key Figures |
|
1998年上半年
1st Half of 1998
￥百万元
millions RMB |
1999年上半年
1st Half of 1999
￥ 百万元
millions RMB |
增长率
Increase |
1998年全年
1998 Whole year
￥ 百万元
millions RMB |
| 销售额(Sales) |
21,696 |
22,344 |
+3% |
43,168 |
| 毛利(Gross profit) |
14,699 |
15,828 |
+8% |
29,457 |
| 运作利润(Operating
profit) |
3,088 |
3,652 |
+18% |
6,192 |
| 净利(Net earnings) |
1,992 |
2,349 |
+18% |
4,291 |
| 资产损益前净利(Net
earning before capital gains and losses) |
1,959 |
2,373.8 |
+21% |
4,109 |
| |
|
|
| 在欧洲 |
| 赛诺菲～圣德拉堡是欧洲第6大制药公司.在中欧和东欧的大型企业中,赛诺菲～圣德拉堡集团计划继续其在俄罗斯、乌克兰、白俄罗斯、保加利亚和罗马尼亚的发展。 |
| in
Europe |
| Sanofi-Synthélabo
is the sixth leading European pharmaceutical company.Among the
leaders in Central and Eastern Europe,the Group aims to continue
its growth in countries such as Russia,the Ukraine,Belarus,Bulgaria
and Romania. |
| 在北美 |
| 由于思诺思®已成为美国市场上首选的催眠药，安博维®和波立维®也成功上市，在当地的销售力量已超过800人，赛诺菲～圣德拉堡已具备足够的能力将其开发的药品直接投放到这一市场中。 |
| In
North America |
| With
Stilnox®,the No1 hypnotic on the U.S. market,the
success of Aprovel® and Plavix®,and
a sales force of more than 800 people,Sanofi-Synthélabo has
the requisite resources to launch compounds from its R&D
organization directly in this market. |
| 在亚太地区 |
| 赛诺菲～圣德拉堡继续争取在中国、泰国、南朝鲜和马来西亚取得更多的市场份额。 |
| In
Asia/Pacific Rim |
| Sanofi-Synthélabo
continues to win market share in China,Thailand,South Korea
and Malaysia. |
| 在日本 |
| 作为备受关注的进口药品生产商，赛诺菲～圣德拉堡和日本的重要公司都有良好的合作关系，如Daiichi,Fujisawa,Meiji,MitsubishiKasei,Taisho和Yamanouchi。 |
| In
Japan |
| In
the front rank of foreign pharmaceutical concerns,Sanofi-Synthélabo
has solid partnerships with the major Japanese companies Daiichi,Fujisawa,Meiji,MitsubishiKasei,Taisho
and Yamanouchi. |
| 在非洲和中东 |
| 赛诺菲～圣德拉堡正在继续加强其在北非说法语的国家、南非和士耳其的力量。 |
| In
Africa and the Middle East |
| In
North Africa,the French-speaking countries of Africa,South-Africa
and Turkey,Sanofi-Synthélabo is strengthening its presence. |
| 在拉丁美洲 |
| 赛诺菲～圣德拉堡有稳固的工业和商业基础，特别是在巴西、墨西哥和阿根廷。 |
| In
Latin America |
| Sanofi-Synthélabo
has a solid industrial and commercial base,particularly in Brazil,Mexico
and Argentina,upon which to build its presence. |
| |
